A midsized life sciences company needed support in prioritizing indications and preliminary clinical activity of a compound with a novel mechanism of action in preclinical development that would be tested in conjunction with chemotherapy upon entering clinical development.
We used CancerMPact®, an oncology decision-support tool for market analysis, strategic planning and identification of commercial opportunities, to develop high-level summaries for multiple tumor types. A rating, weighting and ranking methodology was devised to evaluate a series of product development opportunities.
Interviews were conducted upfront to get the independent thoughts of key members of the client team and to encourage collaboration. We then mediated a workshop to dig deeper into this data with the preclinical, clinical and commercial teams. Breakout groups evaluated each opportunity by line of therapy, highlighting the strengths, weaknesses and information gaps.
We prepared background information on key tumor types. Based on client feedback and our scientific and commercial expertise in oncology, we rated each opportunity and developed material to review during the strategic workshop. During the workshop, the client’s preclinical, clinical and commercial teams reviewed options and selected specific drug combinations to test preclinically. Implementation of these recommendations will drive future clinical development decisions.
The client said, “We hired Kantar Health for its global and local knowledge of the oncology market. The workshop encouraged us to think about several opportunities not previously considered. Kantar Health brought the preclinical, clinical and commercial teams together as a collaborative unit and worked with them to reach commonly agreed goals that will maximize the ROI for future developments.”